RELAY THERAPEUTICS INC's ticker is RLAY and the CUSIP is 75943R102. A total of 148 filers reported holding RELAY THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,111,883 | -52.4% | 132,210 | -29.0% | 0.02% | -46.9% |
| Q2 2023 | $2,337,436 | +38.3% | 186,102 | +81.4% | 0.03% | +14.3% |
| Q1 2023 | $1,689,815 | +4.8% | 102,600 | -5.0% | 0.03% | -6.7% |
| Q4 2022 | $1,612,886 | -49.8% | 107,958 | -24.8% | 0.03% | -46.4% |
| Q3 2022 | $3,211,000 | +42.1% | 143,520 | +6.4% | 0.06% | +40.0% |
| Q2 2022 | $2,259,000 | -72.5% | 134,883 | -50.8% | 0.04% | -47.4% |
| Q1 2022 | $8,209,000 | -66.5% | 274,283 | -65.6% | 0.08% | -45.3% |
| Q4 2021 | $24,468,000 | +1.9% | 796,747 | +4.6% | 0.14% | +11.2% |
| Q3 2021 | $24,018,000 | -21.4% | 761,743 | -8.8% | 0.12% | -16.7% |
| Q2 2021 | $30,572,000 | -56.2% | 835,538 | -58.6% | 0.15% | -60.1% |
| Q1 2021 | $69,847,000 | -18.7% | 2,020,461 | -2.2% | 0.38% | -11.7% |
| Q4 2020 | $85,902,000 | -0.4% | 2,066,931 | +2.0% | 0.43% | -19.9% |
| Q3 2020 | $86,266,000 | – | 2,025,501 | – | 0.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP III, LLC | 10,551,115 | $438,504,000 | 37.66% |
| TRV GP IV, LLC | 2,811,197 | $116,833,000 | 37.48% |
| Foresite Capital Management V, LLC | 400,000 | $16,624,000 | 12.31% |
| Foresite Capital Management IV, LLC | 2,139,380 | $88,913,000 | 9.66% |
| EcoR1 Capital, LLC | 3,200,649 | $133,019,000 | 7.15% |
| BVF INC/IL | 3,073,147 | $127,720,000 | 5.02% |
| Casdin Capital, LLC | 3,808,894 | $158,298,000 | 4.69% |
| SB INVESTMENT ADVISERS (UK) LTD | 27,904,963 | $1,159,730,000 | 4.67% |
| Grace Capital | 164,389 | $6,832,000 | 4.32% |
| Alphabet Inc. | 1,801,490 | $74,870,000 | 3.59% |